Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

RECRUITING

Linezolid Plus Standard of Care

Lead Sponsor:

University Hospital, Basel, Switzerland

Collaborating Sponsors:

Swiss National Science Foundation

Conditions:

Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The aim of the study is to assess whether targeting virulence factors by administering linezolid in addition to standard antibiotic treatment improves outcomes in patients with Staphylococcus aureus b...

Detailed Description

Staphylococcus aureus (S. aureus) is one of the deadliest bacterial pathogens, especially in high-income countries, and causes bloodstream infections (bacteraemia) in 20-30 per 100,000 people annually...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Staphylococcus aureus (S. aureus) grown from at least one blood culture
  • Hospitalised at a participating centre
  • ≥18 years old
  • Written informed consent or fulfilling criteria for an emergency exception from informed consent requirements
  • Exclusion criteria:
  • Administration of the initial drug treatment not feasible within 72 hours since the collection of the first positive blood culture with S. aureus
  • Documented history of positive blood cultures for S. aureus occurring between 72 hours and 180 days prior to the eligibility assessment
  • Necrotising fasciitis
  • Currently receiving linezolid or clindamycin
  • Use of any monoamine oxidase A or B inhibitor within the last two weeks
  • Known hypersensitivity to linezolid or any other ingredients of the study drugs
  • Current severe thrombocytopenia (i.e. \<30 x 10\^9/L)
  • Application of study drug not possible (per mouth or per gastric tube)
  • Currently breastfeeding
  • Local treating team believes that death is imminent and inevitable
  • Patient is receiving end of life care and antibiotic treatment is not considered appropriate
  • Local treating team believes that participation in the study is not in the best interest of the patient
  • Any indication that the patient is unwilling to participate in the study including an advance directive stating such unwillingness

Exclusion

    Key Trial Info

    Start Date :

    October 6 2025

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    October 1 2028

    Estimated Enrollment :

    606 Patients enrolled

    Trial Details

    Trial ID

    NCT06958835

    Start Date

    October 6 2025

    End Date

    October 1 2028

    Last Update

    November 17 2025

    Active Locations (12)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 3 (12 locations)

    1

    Kantonsspital Aarau (KSA)

    Aarau, Canton of Aargau, Switzerland

    2

    St. Claraspital

    Basel, Canton of Basel-City, Switzerland

    3

    Hôpitaux universitaires de Genève (HUG)

    Geneva, Canton of Geneva, Switzerland

    4

    Hôpital du Jura

    Delémont, Canton of Jura, Switzerland